Every branded, FDA-track GLP-1 and incretin drug we follow, approved and in the pipeline, with what it targets, how far along it is, and what's coming next.
Last updated: Jul 13, 2026
Receptors: GLP-1GIPglucagonamylin −GIP = antagonistStage: filled = reached, dark = currentBeyond weight loss: ✓ benefit ~ early signal ⚠ harm · untested
| Molecule | Maker | Targets | Stage | Weight loss | What's next |
|---|---|---|---|---|---|
| tirzepatide Mounjaro (T2D), Zepbound (obesity, OSA) |  | GIPGLP-1 | ✓ Approved | 21% | SURMOUNT-MAINTAIN & cardiovascular outcomes readouts (2026) |
| semaglutide Ozempic (injectable, T2D), Wegovy (injectable, obesity), Wegovy pill (oral semaglutide, obesity), Rybelsus (oral, T2D) |  | GLP-1 | ✓ Approved | 15% | Label expansions ongoing (MASH, oral obesity dose) (2026) |
| orforglipron Foundayo | | GLP-1 | ✓ Approved | 11.2% | Medicare GLP-1 Bridge begins (2026-07-01) |
| cagrilintide + semaglutide CagriSema | | GLP-1amylin | Filed (FDA review) | 22.7% | FDA decision expected (NDA filed Dec 2025) (2026-2027) |
| retatrutide — | | GIPGLP-1glucagon | Phase 3 | 28.3% | TRIUMPH Phase 3 program readouts (2026) |
| ribupatide (KAI-9531 / HRS9531) — |  | GIPGLP-1 | Phase 3 | 23.6% | KaiNETIC global Phase 3 readouts; China NMPA filing submitted (2026-2027) |
| enicepatide (CT-388 / RO7795068) — |  | GIPGLP-1 | Phase 3 | 22.5% | CT388-104 Phase 2 T2D readout; petrelintide + enicepatide fixed-dose combo Phase 2 starting mid-2026 (NCT07589686) (2026) |
| eloralintide — | | amylin | Phase 3 | 20.1% | Phase 3 program initiated (incl. obesity + T2D, NCT07282600) (2026) |
| maridebart cafraglutide MariTide |  | GLP-1−GIP | Phase 3 | 20% | MARITIME Phase 3 program underway (2026) |
| mazdutide — | | glucagonGLP-1 | Phase 3 | 16.65% | Approved in China (2025); no US filing yet (2025) |
| survodutide — |  | glucagonGLP-1 | Phase 3 | 16.6% | LIVERAGE MASH Phase 3 readout expected (2026-H2) |
| VK2735 — |  | GIPGLP-1 | Phase 3 | 14.7% | Phase 3 VANQUISH-1 & -2 enrollment complete; topline expected ~2027 (2026) |
| HRS-7535 / KAI-7535 (oral) — | | GLP-1 | Phase 3 | 11.1% | Global Phase 2 (obesity) readout, US/Australia; China NMPA filing likely (2027) |
| efpeglenatide — |  | GLP-1 | Phase 3 | 9.8% | Korean regulatory filing for obesity (MFDS); launch targeted H2 2026 (2026) |
| brenipatide — | | GIPGLP-1 | Phase 3 | — | RENEW-ALC Phase 3 (AUD); earliest approval ~2028 (2028) |
| amycretin (INN: zenagamtide) — | | amylinGLP-1 | Phase 2 | 22% | Heading into pivotal trials (2026) |
| berobenatide (MET-097i / PF-08653944) — |  | GLP-1 | Phase 2 | 14.1% | 10 pivotal Phase 3 trials in 2026; pitched as first once-monthly GLP-1, with sleep apnea + knee OA expansion planned (2026) |
| elecoglipron (AZD5004 / ECC5004) — |  | GLP-1 | Phase 2 | — | Global Phase 3 program (planned) (2026) |
| aleniglipron (GSBR-1290) — |  | GLP-1 | Early / watch | 16.3% | Heading to Phase 3 (oral pill) (2026) |
| pemvidutide — |  | glucagonGLP-1 | Early / watch | 15.6% | Phase 3 planning; also a positive MASH (liver) trial (2026) |
| petrelintide — | | amylin | Early / watch | 10.7% | Advancing to Phase 3; petrelintide + enicepatide (CT-388) fixed-dose combo Phase 2 starting mid-2026 (NCT07589686) (2026) |
| MET-233i — | | amylin | Early / watch | 8.4% | MET-233i + MET-097i once-monthly combo 12-wk topline (2026) |
| ABBV-295 (GUB014295) — |  | amylin | Early / watch | 7.75% | Advancing toward Phase 2 (2026) |
| AZD6234 — | | amylin | Early / watch | — | Phase 2 weight-loss readout (2026 (H1)) |
Weight loss = peak mean result at the approved (or trial) obesity dose. Diabetes brands and lower doses come in below this; see each drug's card for the per-product breakdown.
Recent updates
- Jul 13, 2026Added a real-world bone/falls signal to semaglutide and tirzepatide beyond_weight_loss from the morning scan: Chen et al., Osteoporos Int (online 11 Jul 2026, DOI 10.1007/s00198-026-08134-y, PMID 42435064). Retrospective TriNetX cohort of adults >=65 with T2D + overweight/obesity, 1:1 matched vs DPP-4 inhibitors: 1-yr femoral fracture lower with semaglutide (0.3% vs 0.5%, HR 0.49; n=27,896) and tirzepatide (0.2% vs 0.4%, HR 0.45; n=12,808); falls also lower (HR ~0.66 both); fracture benefit larger at BMI >=30. Logged as kind=signal (observational, comparator is DPP-4 not placebo) alongside the existing kind=harm BMD/lean-mass entries — the fracture picture is genuinely mixed, not a reversal. Source saved to sources/osteoporos-int-glp1-fracture-fall-2026.md. Also reconciled the ACHIEVE-2 (orforglipron vs dapagliflozin) PubMed 11 Jul 2026 hit against the tracker: it is the same Lancet paper already carried (online-first 8 Jun 2026, PMID 42259339) now assigned its final indexing date — no new data, no change made.
- Jul 8, 2026Added HRS-7535 / KAI-7535 (Kailera/Hengrui oral small-molecule GLP-1 agonist) as a new molecule from the 7 Jul 2026 topline. This is DISTINCT from the already-tracked injectable dual agonist ribupatide (KAI-9531/HRS9531). China Phase 3 HARBOR-1 (obesity): -10.9% at 44 wks / -11.1% at 50 wks at 180 mg (efficacy estimand) vs -2.5% placebo, but heavy GI (vomiting up to 68.6%, nausea ~70%). OUTSTAND-2 (T2D): HbA1c -1.50 to -1.68% vs -1.28% dapagliflozin. Global Phase 2 (US/Australia) with gentler titration reads out 2027. Status set phase3 (China-only Phase 3), mirroring efpeglenatide/ribupatide. Source: Kailera/GlobeNewswire press release.
- Jul 4, 2026Survodutide SYNCHRONIZE-1 citation + body-composition upgrade. Obesity trial now published in NEJM (7 Jun 2026, DOI 10.1056/NEJMoa2600751, PMID 42253238): added to papers[], status reported->published, and repointed the trial + efficacy source from the Boehringer press release to the NEJM paper. Added the ADA 2026 MRI body-composition substudy (lean mass <=10.8% of tissue change, visceral fat -34%, liver fat -63%, 61% liver-fat normalization) WITH the caveat that it is MRI not DEXA — so NOT evidence of a unique muscle-sparing edge vs DEXA-measured drugs (semaglutide looks similar by MRI; cf. the retatrutide muscle-sparing overclaim). Prompted by the Cremieux/Nadolsky X exchange.
- Jun 11, 2026Added enicepatide (Roche/Carmot CT-388, now with INN; RO7795068) as a new molecule from the ADA 2026 wrap: Phase 2 CT388-103 22.5% placebo-adjusted at 48 wks (efficacy estimand; 18.3% treatment-regimen), 5.9% AE discontinuation; two Phase 3 obesity trials recruiting since Mar 2026 (NCT07351045/58). Petrelintide entry cross-referenced to the new name; combo Phase 2 NCT07589686 starts mid-2026.
- Jun 10, 2026Journal-citation upgrades from morning scan: ACHIEVE-2 promoted reported->published (Lancet, 8 Jun 2026, DOI 10.1016/S0140-6736(26)00800-7); ACHIEVE-3 source upgraded from Lilly PR to Lancet DOI (10.1016/S0140-6736(26)00202-3, published Mar 2026); both added to orforglipron papers[]. REIMAGINE 1-3, ACHIEVE-5 (JAMA) and TRANSCEND-T2D-1 already carried journal DOIs.
- Jun 9, 2026ADA 2026 follow-ups from morning scan: (1) Retatrutide TRIUMPH-4 promoted reported->full data (ADA 2026) with detail — weight -28.7% (12 mg) / -26.4% (9 mg) vs -2.1% placebo at 68 wks, WOMAC knee-pain -74-76% vs -40% placebo, 12-14% pain-free vs 4.2%; source switched to medical.lilly.com. (2) Orforglipron ATTAIN-1/-2 menopause post-hoc added (peri -14.4%/-30.4 lb, post -14.1%, pre -12.8%; >1,500 women; ADA 7 Jun). (3) Class-level cancer signal added to semaglutide beyond_weight_loss: GLP-1 RA users had 41% lower obesity-associated cancer incidence (HR 0.59, Annals of Oncology 2026, PMID 42252247; observational). (4) Heart-failure RCTs added: semaglutide STEP-HFpEF (NEJM 2023) and tirzepatide SUMMIT (NEJM 2025).
- Jun 8, 2026CagriSema REIMAGINE 1-3 peer-reviewed (7 Jun 2026): REIMAGINE 1 & 2 in Lancet Diabetes & Endocrinology, REIMAGINE 3 in The Lancet. All three trials promoted reported->published with DOIs; REIMAGINE 2 confirmed superior to semaglutide 2.4 mg in T2D (A1C -1.91% vs -1.76%, weight -14.2% vs -10.2%, 43% lost >=15%).
- Jun 7, 2026Retatrutide TRIUMPH-1 full obesity data presented at ADA 2026 (n=2,339, 80 wks): -28.3% weight at 12 mg (-25.9% at 9 mg, -19.0% at 4 mg), 65.3% reached BMI <30. Secondary endpoints at 12 mg: knee-osteoarthritis pain -73.1%, obstructive sleep apnea events -60.6%, triglycerides -41%, systolic BP -12.3 mmHg. Tolerability cost: 11.3% discontinued at 12 mg for adverse events vs 4.9% placebo.
- Jun 7, 2026Retatrutide heart-rhythm early signal logged (one to watch, not a verdict): in TRANSCEND-T2D-1 (n=403 treated) 7 patients had arrhythmias and 3 had major cardiovascular events vs 0 on placebo, with pulse up ~1 bpm. Because the glucagon arm can raise heart rate, it is the receptor to monitor, but trial investigators (Bajaj, Drucker, Seeley) call the case counts too small to draw conclusions; the dedicated cardiovascular-outcomes trial reads out ~2029.
- Jun 7, 2026JAMA published two phase 3 incretin trials together: mazdutide GLORY-2 (9 mg, n=461 Chinese adults with obesity, -16.65% mean weight at 60 wks, 42% lost >=20%) and orforglipron ACHIEVE-5 (n=546, add-on to insulin glargine, HbA1c down up to 1.88% at 40 wks), with a joint editorial (Gadde/Heymsfield). GLORY-2 added to trials/papers; ACHIEVE-5 promoted reported->published. Numbers reconciled to the published JAMA figures (earlier 20.1%/2.1% press estimands replaced).
- Jun 7, 2026ADA 2026 day 3: mazdutide DREAMS-3 added (beat semaglutide head-to-head in Chinese T2D + obesity); elecoglipron (AstraZeneca/Eccogene oral GLP-1, AZD5004) added as a new pipeline molecule heading to Phase 3.
- Jun 6, 2026Retatrutide TRANSCEND-T2D-1 published in The Lancet. Early type 2 diabetes monotherapy: HbA1c down 1.94% and weight down 15.3% at 12 mg; dysesthesia milder in T2D (2-4%).
- Jun 6, 2026ADA 2026 readouts added: orforglipron ACHIEVE-2/4/5, CagriSema REIMAGINE 1-3, zenagamtide (amycretin) phase 2, survodutide SYNCHRONIZE-1, berobenatide (Pfizer) VESPER-1/2/3.
- Jun 6, 2026Retatrutide dysesthesia and UTI safety signal logged (up to ~21% dysesthesia at 12 mg in the TRIUMPH-4 obesity trial). Berobenatide promoted to phase 2 with Pfizer's once-monthly strategy.
The pipeline moves fast. I keep this current.
Every trial readout and FDA decision, tracked. Get the updates in your inbox. Free, no spam.
Subscribe on Substack